In preliminary investigations,'-3 we found low concentrations of the dopamine metabolite homovanillic acid (HVA) The aim of the present double blind clinical trial was to verify the possible efficacy of AH (Symmetrel) treatment in Friedreich's ataxia and olivopontocerebellar atrophies, using simple reaction time (RT) and movement time (MT) assessments exclusively as strictly objective measures.
Materials and methods

METHODS
Routine neurological examinations as well as a reinforcement technique for detecting latent parkinsonian rigidity5 and akinesia were performed independently by two neurologists (MIB and OLP). The degree of ataxia of the upper and lower limbs was evaluated clinically as mild, moderate, or severe according to previously established criteria.6 Ataxia in patients with olivopontocerebellar atrophies was assessed for both upper and lower limbs. In patients with Friedreich's ataxia, it was done only for the upper limbs because the patients were already paraplegic. Hand grip strength was evaluated with a Smedley dynamometer7; those who were unable to show a minimum grip strength of 5 kg with each hand were considered to have severe motor disturbances and were consequently ruled out from the study. The rationale for this decision was that patients with a grip strength of 5 kg are capable of pressing the RT key with a minimum force of 5 g. Every two to three weeks during the trial, the patients were telephoned to obtain information about medication compliance and possible side effects. During a visit at the end of the trial, the patients had to respond to two written questionnaires: one on possible side effects and the other about their subjective assessment of treatment. The questionnaire on side effects included insomnia, nightmares, hallucinations, depression, difficulties in concentrating, blurred vision, dizziness, loss of appetite, weight loss, and constipation. The questionnaire on the subjective assessment of treatment included general condition and mood, coordination of the upper limbs, self evaluation of dysarthria, and some specific abilities in everyday life such as the time required to cut or chop vegetables or meat for meals. In addition, patients who could walk (usually patients with olivopontocerebellar atrophy) were required to evaluate their gait and their ability to turn around, and the possibility and time required for transfer from a chair to the bath. We also evaluated the number of falls during treatment, taking as baseline the number of falls during a three month period preceding inclusion in the study. Patients were considered improved when the answers were positive for at least three variables from the above mentioned questionaire and evaluation of the number of falls.
As in our previous open study,3 the reasons for using RT and MT as objective pretreatment and post-treatment assessments in this trial were twofold: (1) no practice effects occur in RT and MT tests8 10; (2) earlier work in our laboratory has shown lengthened RT and MT in patients with cerebellar disease.1 [1] [2] [3] Recognised as one of the best behavioural measures of CNS integrity,"146 RT primarily reflects the speed and efficiency of information processing." Although RT with Friedreich's ataxia from a pool of 40 patients were included in the study. One female patient receiving active medication was taken out of the trial because of severe sleep disorders, hallucinations, and nightmares.
All patients with Friedreich's ataxia included in the trial fulfilled the diagnostic criteria of Harding.20 Of the 27 patients who completed the clinical trial, 23 had polyneuropathies and four were diabetic. All had a bilateral cerebellar and upper motor neuron syndrome, as shown by bilateral Babinski's signs. Twelve had dorsolumbar scoliosis. Sixteen were confined to wheelchairs and the remaining 11 had a severe ataxic gait. Dysmetria and coordination disorders of the upper limbs were: moderate-severe (eight patients), moderate (10 patients), or mild (nine patients). All were right handed. Brain CT showed cerebellar atrophy in 22 patients whereas the others were normal.
Initially, 36 patients with olivopontocerebellar atrophies from a pool of 46 patients were included in this study and received AH tablets. Six of them were dropped from the study. Three of these (two women, one man) receiving placebo were not compliant with the medication. A fourth man also receiving placebo, stopped the medication because of gastrointestinal side effects. Two patients with olivopontocerebellar atrophies (one woman, one man) on active medication dropped out because of a severe sleep disorder and loss of weight respectively. Whereas the sleep disorder occurred during the first three weeks and disappeared after stopping medication, the severe weight loss in the male patient (from 100 kg to 73 kg) took place after one month of treatment.
The number of withdrawals from the sub- Gaspe county. Additionally, we included three patients with recessive and two others with sporadic forms of olivopontocerebellar atrophy; in these patients, the diagnosis was made exclusively on clinical grounds. These four groups correspond to forms 3, 5, 1, and 2 of olivopontocerebellar atrophy from the clinical classification we used. 24 Dysmetria and coordination disorders of the upper limbs were: moderate-severe (eight patients), moderate (nine patients), and mildmoderate (13 patients). Eight patients were confined to wheelchairs; the others had moderate (10 patients) and mild (12 patients) lower limb ataxias. Twelve had polyneuropathies. Four presented bilateral Babinski's signs. They did not have even mild parkinsonian signs, as evaluated by reinforcement methods. 5 The condition of patients with Friedreich's ataxia and patients with olivopontocerebellar atrophies was stable, and they had no other medical or neurological disease. All patients with Friedreich's ataxia underwent clinical cardiological evaluation with ECGs, echocardiograms, and radioisotope ventriculography before entering the trial.
STUDY DESIGN
Both patient groups were admitted to hospital for four to five days in the metabolic ward of Hotel-Dieu de Montreal Hospital before the trial.
Each group was randomly divided into two subgroups, one receiving two AH tablets of 100 mg each, and the other, two placebo tablets of identical size, shape, and colour as the AH tablets. Patients were included randomly in order of presentation at the outpatient clinic. Randomisation was done by KG. The neurologists (MIB and OLP) as well as the neuropsychologist (TBM) were unaware at all times of the nature of treatment given to each patient. The protocol was approved by the research ethics board of Hotel-Dieu de Montreal Hospital, and all patients gave their informed consent.
Treatment was given to each patient for three to four months. This lapse of time was necessary because of the availability of patients who came (many of them) from Gaspe county, about 500 miles from Montreal, and also because of climatic conditions-namely, the long Canadian winter. Due to such conditions, one patient with olivopontocerebellar atrophy from Gaspe county was examined after five months (table 1) . At the end of the trial, the patients answered questionnaires about their subjective feelings and the side effects of treatment; assessments of RT and MT were performed on the same day and at the same hour as the baseline evaluation.
Both objective (RT, MT) and clinical neurological evaluations were recorded in the files before information about treatment was disclosed by the pharmacist (KG) at the end of the trial.
STATISTICS
Differences in RT and MT post-treatment values from baseline were assessed for significance within each subgroup by analysis of variance (ANOVA). The comparative effects of AH and placebo were evaluated by two way (two drug treatments by two diseases) analysis of covariance (ANCOVA) in which baseline values served as covariates for outcome values. A single common slope of regression was used whenever heterogeneity of regression was not seen at 10%. In this case, the slopes for the two categories of patients or those of the two drug treatments were used in multiple regression analysis.
Results Table 1 gives the clinical characteristics of the patients. The patients with Friedreich's ataxia were younger than patients with olivopontocerebellar atrophies but their illness was of significantly longer duration. There was no significant difference in the duration of treatment between patients with Friedreich's ataxia and those with olivopontocerebellar atrophies (F1,5, = 0 74, NS). The mean duration of placebo treatment was mean (SEM) 3-68 (0-138) months whereas the mean duration for active treatment was 3-72 (0 187) months. The difference was not statistically significant (F1,53 = 0-01,NS).
No improvement was seen in both subgroups of patients with Friedreich's ataxia in terms of their lower limbs on both subjective assessment and neurological examination.
Subjective improvement on the self evaluation questionaire was reported by 22 patients, nine with Friedreich's ataxia and 13 with olivopontocerebellar atrophies. Except for four patients, all those who reported improvement had been treated with AH (P < 0-002).
At the end of treatment, neurological examination (blind assessment of ataxias in the upper limbs) indicated that 15 out of 29 patients were improved with AH and one of 28 was improved with placebo (P < 0-0001). Improvement with the active drug was found in patients with Friedreich's ataxia (P < 0 05) and patients with olivopontocerebellar atrophies (P < 0-001). In terms of magnitude of this effect, the ataxia scores at the level of the upper limbs were improved by 20% in patients with Friedreich's ataxia and 35% in patients with olivopontocerebellar atrophies.
In terms of side effects during treatment, which was not discontinued during the trial, two patients receiving AH had some loss of appetite during the third month. A third (2) there is right hemispheric superiority for sustained attention tasks,39 a function which is basically involved in both RT and MT performances; (3) the mesolimbic dopamine system is implicated in incentive motivational processes by which evaluative processes are translated into action; whereas this sustained attentional system is underlaid mainly by dopaminergic mesolimbic projections,36 selective attentional and arousal mechanisms are underpinned by noradrenergic projections40; moreover, the mesolimbic system is also intimately involved in the control of motor behaviour and higher integrative functions36 41; (4) in both humans and animals, relatively higher concentrations of dopamine are found in the left hemisphere than in the right42 whereas the reverse is true for noradrenaline. 43 Our hypothesis concerning this handedness difference is that the dopaminergic deficit could be partially responsible for the better improvement of RT and MT performances because sustained attention is mostly dependent on the mesocortical dopaminergic system. The lowering of dopamine concentration involves both hemispheres in our patients with Friedreich's ataxia and patients with olivopontocerebellar atrophy, but: (a) the dopamine pool is initially higher in the left hemisphere, thus corresponding to the right hand42; (b) the lowering of dopamine concentration in the right hemisphere, which is dominant for sustained attention, could explain why replacement therapy would improve primarily the function of the left hand.
Although the impact of AH on dopamine release44 may explain some of its therapeutic actions, this was certainly not the only factor involved for two reasons: (1) levodopa treatment did not induce an improvement of olivopontocerebellar atrophies45; (2) there was no parallelism between low CSF concentrations and improvement of patients with olivopontocerebellar atrophies in a previous open study. 3 Secondly, earlier work21 46 has emphasised the possible role of glutamate toxicity in olivopontocerebellar atrophies. Glutamate turnover is high in the granule cell layer; granule cells, the predominant target of mossy fibres, seem to possess NMDA and at least one non-NMDA glutamate receptor. They are, therefore, able to respond to presynaptic glutamate mediated mossy fibre transmission. 46 Thirdly, the neuronal damage associated with neurodegenerative disorders may be related to excitation of NMDA receptors.47 It has been shown that the neurotoxicity of glutamate and closely related agonists is mediated by NMDA receptors in cultured cerebellar granule cells. [48] [49] [50] Fourthly, memantine, an AH analogue, is a potent blocker of NMDA receptor channels.5-5' We think that the action of AH on NMDA receptor channels provides another main explanation for the improvement found in our cases. In lurcher mutant mice, an animal model of olivopontocerebellar atrophy, amantadine and the NMDA receptor antagonist, ketamine, improved motor coordination in the coat hanger test.53
In summary, In this double blind clinical trial, (1) AH treatment for three to four months significantly improved some RT and MT scores (the speed of information processing, attention and motivation as well as motor performance evaluated at the level of the upper limbs only). (2) This study confirms some previous open clinical trials,lA but it must be underscored that on the whole improvement was more moderate than previously reported. 4 Filla et al54 found a negative effect in patients with Friedreich's ataxia receiving a single 100 mg dose of AH with ataxia scores recorded 90 minutes later. Their study is not directly comparable with the above cited investigations because of its acute nature. AH must be generally considered as replacement treatment, and its clinical action most probably requires more than 90 minutes. (3) In this short term trial, clinical improvement of motor coordination was striking in many cases of olivopontocerebellar atrophy, whereas it was mild or absent in patients with Friedreich's ataxia although their condition remained stable or was mildly improved objectively. (4) Finally, treatment with AH is justified for trial based on experimental data and the results of this study. The main difficulty with such treatments in these disorders is that neurotransmitter deficiencies are probably multifactorial.32 
